Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer: Results of randomized trial after 21 months of follow-up
Open Access
- 31 July 1992
- Vol. 40, 11-15
- https://doi.org/10.1016/0090-4295(92)90530-a
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pigUrological Research, 1989
- Does bacillus Calmette-Guérin immunotherapy accelerate growth and cause metastatic spread of second primary malignancy?Urology, 1988
- Intravesical and Intradermal Bacillus Calmette-Guérin ApplicationEuropean Urology, 1988
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.Journal of Clinical Oncology, 1987
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987
- The effects of intravesical and intradermal application of a new B.C.G. on the dog bladderUrological Research, 1986
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a reviewWorld Journal of Urology, 1985
- The Management of Superficial Bladder CancerCancer, 1980